Cell-based therapy shows promise against Type-1 diabetes

30

Toronto, May 23 | An islet cell transplant programme developed by a team of Canadian researchers is a safe, reliable and life-changing treatment for people with hard-to-control Type 1 diabetes.

Islets are clusters of cells which produce insulin, a hormone that allows the body to control the flow of energy from food, storing the excess after meals and releasing it to allow the body to function between meals.

In Type 1 diabetes, the immune system mistakenly destroys the cells within islets so patients have to take insulin by injection. Patients with hard-to-control or “brittle” diabetes face life-threatening low or high blood sugars and long-term complications.

“We’ve shown very clearly that islet transplantation is an effective therapy for patients with difficult-to-control Type 1 diabetes,” said James Shapiro, Professor of surgery at the University of Alberta. “This long-term safety data gives us confidence that we are doing the right thing.”

“This data shows really strong proof that cell-based therapies can deliver a meaningful and transformative impact for people with diabetes,” added Peter Senior, director of the Alberta Diabetes Institute at the varsity.

“We are delivering something which all other treatments for diabetes don’t deliver — there’s a comfort, a predictability, a stability to blood sugar levels that don’t exist with anything else.”

In the study published in The Lancet Diabetes & Endocrinology, the researchers report on patient survival, graft survival, insulin independence and protection from life-threatening low blood sugars for 255 patients who have received a total of more than 700 infusions of islets at the University of Alberta Hospital between March 1999 and October 2019.

The results showed that 70 per cent of the grafts survived for a median time of nearly six years, 79 per cent of the transplant recipients were able to stop taking insulin after two or more islet infusions and a median time of 95 days following the first transplant.

About 61 per cent were still insulin-independent a year later, 32 per cent at five years and eight per cent after 20 years, the researchers reported. While most patients had to resume taking insulin injections, the doses were usually much smaller than their original needs and their diabetes control was better.

“Being completely free of insulin is not the main goal,” said Shapiro. “It’s a big bonus, obviously, but the biggest goal for the patient – when their life has been incapacitated by wild, inadequate control of blood sugar and dangerous lows and highs – is being able to stabilise. It is transformational.”

Source: IANS

Post Disclaimer by BhaskarLive.in

The information contained in this post is source form the news agency or PR agency. We do not take any responsibility of accuracy of information. We have not made any modification or changes in original source content. This information only for general information purposes only. The information is provided by BhaskarLive.in and while we Endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.

Next Story

Weekly Fundamental Market Outlook

Weekly Fundamental Market Outlook

Indian share market posted its first weekly gain in Jun by rising 2.7%.

This week, the Indian Stock Market rebounded strongly and ended with first weekly gain of 2.7% in June as a drop in commodity prices offered some relief from broadening inflationary pressures. Copper prices, which are often seen as a bellwether for economic output due to their wide range of industrial and construction uses, are heading for their worst week in a year, while oil prices have dropped over concerns of slumping demand.

While the US recessionary fears are still at the forefront, but the slide in commodity prices has lifted the mood of stock market.Cheaper oil is usually beneficial for oil-importing countries such as India.

Domestically, on sectorial basis, Auto and FMCG are the top gainers, while Metal index is the top losers. On stock basis, Hero MotoCorp, Eicher Motors, Hindustan Unilever, Maruti Suzuki and M&M were the top gainers and Tata steel, UPL, Reliance Industries, hindalco Inds and Coal India were the top losers.

In the next week, investors will keep a close eye on crude oil price movement, commodity prices, US economic activity and the geopolitical development.

 

Post Disclaimer by BhaskarLive.in

The information contained in this post is source form the news agency or PR agency. We do not take any responsibility of accuracy of information. We have not made any modification or changes in original source content. This information only for general information purposes only. The information is provided by BhaskarLive.in and while we Endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.

LEAVE A REPLY

Please enter your comment!
Please enter your name here